2023
Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults — United States, December 2020–March 2023
Montoy J, Ford J, Yu H, Gottlieb M, Morse D, Santangelo M, O’Laughlin K, Schaeffer K, Logan P, Rising K, Hill M, Wisk L, Salah W, Idris A, Huebinger R, Spatz E, Rodriguez R, Klabbers R, Gatling K, Wang R, Elmore J, McDonald S, Stephens K, Weinstein R, Venkatesh A, Saydah S, Group I, Group I, Ahmed Z, Choi M, Derden A, Gottlieb M, Guzman D, Hassaballa M, Jerger R, Kaadan M, Koo K, Yang G, Dorney J, Kinsman J, Li S, Lin Z, Mannan I, Pierce S, Puente X, Ulrich A, Yang Z, Yu H, Adams K, Anderson J, Chang G, Gentile N, Geyer R, Maat Z, Malone K, Nichol G, Park J, Ruiz L, Schiffgens M, Stober T, Willis M, Zhang Z, Amadio G, Charlton A, Cheng D, Grau D, Hannikainen P, Kean E, Kelly M, Miao J, Renzi N, Shughart H, Shughart L, Shutty C, Watts P, Kane A, Nikonowicz P, Sapp S, Gallegos D, Martin R, Chandler C, Eguchi M, L’Hommedieu M, Moreno R, Roldan K, Arreguin M, Chan V, Chavez C, Kemball R, Wong A, Briggs-Hagen M, Hall A, Plumb I. Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults — United States, December 2020–March 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 859-865. PMID: 37561663, PMCID: PMC10415002, DOI: 10.15585/mmwr.mm7232a2.Peer-Reviewed Original ResearchConceptsCOVID-like illnessSARS-CoV-2 test resultsPost-COVID conditionsNegative SARS-CoV-2 test resultsPositive SARS-CoV-2 test resultProspective multicenter cohort studySARS-CoV-2 infectionMulticenter cohort studyPrevalence of symptomsTime of enrollmentCOVID-19 testing statusHealth care providersSARS-CoV-2Self-reported symptomsCohort studyPersistent symptomsAcute illnessAntigen testPolymerase chain reactionClinical signsSymptom progressionCare providersDrug AdministrationTesting statusSymptomsAtorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial
Talasaz A, Sadeghipour P, Bakhshandeh H, Sharif-Kashani B, Rashidi F, Beigmohammadi M, Moghadam K, Rezaian S, Dabbagh A, Sezavar S, Farrokhpour M, Abedini A, Aliannejad R, Riahi T, Yadollahzadeh M, Lookzadeh S, Rezaeifar P, Matin S, Tahamtan O, Mohammadi K, Zoghi E, Rahmani H, Hosseini S, Mousavian S, Abri H, Sadeghipour P, Baghizadeh E, Rafiee F, Jamalkhani S, Amin A, Mohebbi B, Parhizgar S, Soleimanzadeh M, Aghakouchakzadeh M, Eslami V, Payandemehr P, Khalili H, Talakoob H, Tojari T, Shafaghi S, Tabrizi S, Kakavand H, Kashefizadeh A, Najafi A, Jimenez D, Gupta A, Madhavan M, Sethi S, Parikh S, Monreal M, Hadavand N, Hajighasemi A, Ansarin K, Maleki M, Sadeghian S, Barco S, Siegerink B, Spatz E, Piazza G, Kirtane A, Tassell B, Lip G, Klok F, Goldhaber S, Stone G, Krumholz H, Bikdeli B. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial. Thrombosis And Haemostasis 2023, 123: 723-733. PMID: 36944357, DOI: 10.1055/a-2059-4844.Peer-Reviewed Original ResearchConceptsExtracorporeal membrane oxygenationArterial thrombosisMAIN OUTCOMEAtorvastatin 20Symptom onsetICU patientsFunctional statusIntensive care unit patientsCOVID-19Double-blind multicenterAdult ICU patientsCare unit patientsThrombo-inflammatory responseCoronavirus disease 2019Meaningful treatment effectPrespecified studyCause mortalityAtorvastatin useUnit patientsMembrane oxygenationFunctional outcomeDisease 2019Functional scalesPlaceboPatientsRoutine saliva testing for SARS-CoV-2 in children: Methods for partnering with community childcare centers
Rayack E, Askari H, Zirinsky E, Lapidus S, Sheikha H, Peno C, Kazemi Y, Yolda-Carr D, Liu C, Grubaugh N, Ko A, Wyllie A, Spatz E, Oliveira C, Bei A. Routine saliva testing for SARS-CoV-2 in children: Methods for partnering with community childcare centers. Frontiers In Public Health 2023, 11: 1003158. PMID: 36817891, PMCID: PMC9936085, DOI: 10.3389/fpubh.2023.1003158.Peer-Reviewed Original ResearchConceptsParents/guardiansOnline patient portalYounger age groupsSARS-CoV-2Age groupsSurveillance programSaliva collectionSARS-CoV-2 testingSARS-CoV-2 screeningWeekly saliva samplesRT-PCR testingChildcare centre staffCritical age groupRoutine surveillance toolRoutine testing programsChildcare centersCOVID-19 transmissionAsymptomatic screeningSaliva collection methodNasal swabsPatient portalsSymptomatic testingPublic health dataSaliva samplesChildcare facilities
2022
Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group
Spatz E, Gottlieb M, Wisk L, Anderson J, Chang A, Gentile N, Hill M, Huebinger R, Idris A, Kinsman J, Koo K, Li S, McDonald S, Plumb I, Rodriguez R, Saydah S, Slovis B, Stephens K, Unger E, Wang R, Yu H, Hota B, Elmore J, Weinstein R, Venkatesh A. Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group. Clinical Infectious Diseases 2022, 76: 1559-1566. PMID: 36573005, DOI: 10.1093/cid/ciac966.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 symptomsSARS-CoV-2 infectionPost-infectious syndromesProspective cohort studyCohort studyCOVID groupAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 test resultsSyndrome coronavirus 2 infectionEar/nose/throatSevere acute respiratory syndrome coronavirus 2 testsCoronavirus 2 infectionLong-term symptomsNose/throatLong COVIDSymptomatic adultsMean ageActive symptomsSymptom profilesDrug AdministrationSociodemographic characteristicsSymptomsInfectionMonthsAssociation of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness
Wisk L, Gottlieb M, Spatz E, Yu H, Wang R, Slovis B, Saydah S, Plumb I, O’Laughlin K, Montoy J, McDonald S, Lin Z, Lin J, Koo K, Idris A, Huebinger R, Hill M, Gentile N, Chang A, Anderson J, Hota B, Venkatesh A, Weinstein R, Elmore J, Nichol G, Santangelo M, Ulrich A, Li S, Kinsman J, Krumholz H, Dorney J, Stephens K, Black K, Morse D, Morse S, Fernandes A, Sharma A, Stober T, Geyer R, Lyon V, Adams K, Willis M, Ruiz L, Park J, Malone K, Shughart H, Schaeffer K, Shughart L, Arab A, Grau D, Patel A, Watts P, Kelly M, Hunt A, Hannikainen P, Chalfin M, Cheng D, Miao J, Shutty C, Chavez S, Kane A, Marella P, Gallegos G, Martin K, L'Hommedieu M, Chandler C, Diaz Roldan K, Villegas N, Moreno R, Eguchi M, Rodriguez R, Kemball R, Chan V, Chavez C, Wong A, Hall A, Briggs-Hagen M. Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness. JAMA Network Open 2022, 5: e2244486. PMID: 36454572, PMCID: PMC9716377, DOI: 10.1001/jamanetworkopen.2022.44486.Peer-Reviewed Original ResearchConceptsCOVID-19 positive groupCOVID-19-negative groupSARS-CoV-2 infectionCOVID-19 testCOVID-19 resultsSymptomatic illnessSymptomatic SARS-CoV-2 infectionNegative COVID-19 resultsSARS-CoV-2 statusSARS-CoV-2 test positivityPositive COVID-19 testSARS-CoV-2 testNegative COVID-19 testLongitudinal registry studyOutcomes Measurement Information SystemPatient-reported outcomesHealth care usePositive COVID-19 resultMultivariable regression analysisMeasurement Information SystemCOVID-19 testingNegative test resultsCohort studyRegistry studyPROMIS scoresDurable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes
INVESTIGATORS I, Sadeghipour P, Talasaz A, Barco S, Bakhshandeh H, Rashidi F, Rafiee F, Rezaeifar P, Jamalkhani S, Matin S, Baghizadeh E, Tahamtan O, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M, Sezavar S, Payandemehr P, Dabbagh A, Moghadam K, Jimenez D, Monreal M, Maleki M, Siegerink B, Spatz E, Piazza G, Parikh S, Kirtane A, Van Tassell B, Lip G, Goldhaber S, Klok F, Krumholz H, Bikdeli B. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. European Journal Of Internal Medicine 2022, 103: 76-83. PMID: 35879217, PMCID: PMC9212871, DOI: 10.1016/j.ejim.2022.06.014.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsCOVID-19Critical CareFemaleHospitalizationHumansMaleMiddle AgedSARS-CoV-2ConceptsStandard-dose prophylactic anticoagulationPatient Health Questionnaire-2Proportion of patientsProphylactic anticoagulationIntermediate doseFunctional limitationsDepressive symptomsFunctional outcomeCOVID-19Intensive care unit hospitalizationCritically Ill PatientsMultiple organ failureSevere functional limitationsFunctional Status ScaleCoronavirus disease 2019Open labelExercise limitationAirway diseaseICU patientsOrgan failureIntensive careStatus ScaleClinical trialsGrade 3AnticoagulationShort-Term Outcomes After Myopericarditis Related to COVID-19 Vaccination
Pareek M, Steele J, Asnes J, Baldassarre L, Casale L, Desai N, Elder R, Faherty E, Ferguson I, Fishman R, Ghazizadeh Z, Glick L, Hall E, Khera R, Kokkinidis D, Kwan J, O'Marr J, Schussheim A, Tuohy E, Wang Y, Spatz E, Jacoby D, Miller E. Short-Term Outcomes After Myopericarditis Related to COVID-19 Vaccination. JACC Cardiovascular Imaging 2022, 15: 2002-2005. PMID: 36357140, PMCID: PMC9094612, DOI: 10.1016/j.jcmg.2022.03.026.Peer-Reviewed Case Reports and Technical Notes